Radium and targeted alpha therapy in prostate cancer: new data and concepts
Open Access
- 6 January 2020
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (2), 165-166
- https://doi.org/10.1016/j.annonc.2019.12.005
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancerAnnals of Oncology, 2020
- Advances in targeted alpha therapy for prostate cancerAnnals of Oncology, 2019
- Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand TherapyJournal of Nuclear Medicine, 2019
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2019
- Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic WindowJournal of Nuclear Medicine, 2018
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor ControlJournal of Nuclear Medicine, 2018
- Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyCurrent Radiopharmaceuticals, 2015
- Revision of the NIST Standard for 223 Ra: New Measurements and Review of 2008 DataJournal of Research of the National Institute of Standards and Technology, 2015
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2013
- Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studyThe Lancet Oncology, 2007